

STRICTLY PRIVATE AND CONFIDENTIAL

## **ANTARES VISION** FOR A HEALTHIER AND SAFER WORLD

**COMPANY PRESENTATION** APRIL 2021





## AGENDA

| 1. COMPANY OVERVIEW            | 3   |
|--------------------------------|-----|
| 2. KEY INVESTMENT HIGHLIGHTS   | 11  |
| 3. MARKET & COMPETITION        | 22  |
| 4. SOLUTIONS OFFERING          | 40  |
| 5. FOCUS ON INNOVATION         | 59  |
| 6. CUSTOMER BASE & CROSS-SELL  | 69  |
| 7. BUSINESS MODEL & OPERATIONS | 76  |
| 8. FINANCIAL PERFORMANCE       | 89  |
| 9. GROWTH STRATEGY             | 100 |
|                                |     |






Section 1

## **COMPANY OVERVIEW**

#### FOUNDER-LED MANAGEMENT TEAM





Leading the complete process of protecting **products**, **people** and **brands** throughout their life-cycle, **Antares Vision** delivers the most comprehensive and scalable global solutions in **Inspection Systems**, **Track & Trace** and **Smart Data Management**. Driven by **competence**, **energy** and **passion**, we have fun in providing **innovative technologies** and developing strong partnerships with our customers to co-create **added value** 

# ANTARES VISION: A LEADER IN TRACK & TRACE, INSPECTION AND SMART DATA MANAGEMENT FOR LIFE SCIENCE AND F&B




ANTARESVISION DUR TECHNOLOGY, YOUR SAFETY.

Leading market positions in track & trace, inspection and smart data across attractive Life Science and Food & Beverage end markets

Knowledge and expertise to enhance the value of our clients' product through every stage of the supply chain

SERVING MORE THAN 2,500 CUSTOMERS <sup>(7)</sup>



Sources: Company Information Notes

- 1. Revenue breakdown based on 2020A reported results
- 2. Workforce Pro-Forma at Group level
- 3. 2020A Pro-Forma for the acquisition of rfXcel
- 4. Pro-Forma results including 12m contribution from Tradeticity, Convel, Applied Vision, rfXcel, Pen-Tec and Tecnel

7.

6

5. 2012-2017 figures based on ITA GAAP, 2018-2020 figures based on IAS/IFRS
6. Gross margin defined as (Revenues – COGS) / Revenues
7. Active and non-active cumulated customers since foundation

### UNIQUE END-TO-END SOLUTION FOR THE DIGITAL SUPPLY CHAIN



#### COMPLETE & NATIVE BORNE **SOFTWARE** SUITE

Modular **Software** capabilities managing massive data storage and information flow, optimizing factory operations and enhancing supply chain visibility

#### AI POWERED SMART DATA MANAGEMENT

Smart Data Management brings new synergies and added value through data storage, data analytics and business intelligence

#### 360° SERVICE, MAINTENANCE & SUPPORT

24/7 **Services** including after sales support, training, remote assistance, on-site maintenance and spare parts

#### LEADING TRACK & TRACE SOLUTIONS

Track & Trace solutions to identify and trace products from the origin to the end user, at every stage of the supply chain

#### INNOVATIVE MACHINE VISION & INSPECTION SYSTEMS

Inspection systems and automatic machines to guarantee integrity and conformity of products, containers and packaging

ANTARESVISION


## EXPANDING END-MARKET EXPOSURE WITH LARGE RUNWAY BEYOND LIFE SCIENCE



ONE-STOP-SHOP FOR LIFE SCIENCE AND F&B, WITH INCREASING PRESENCE IN OTHER END-MARKETS

#### ANTARES VISION OFFERING BY TECHNOLOGY AND END-MARKET


GROWING EXPOSURE BEYOND LIFE SCIENCE



REVENUE BY END-MARKET - %

#### TIMELINE OF ANTARES VISION'S SUCCESS






© 2021 Antares Vision

9

#### STRONG TRACK-RECORD OF RAPID GROWTH AND MARGIN EXPANSION **ANTARESVISION**



3. Assets acquired

10





Section 2

## **KEY INVESTMENT HIGHLIGHTS**

### ANTARES VISION STORY IN A NUTSHELL



A leader in track & trace, inspection and smart data management for the life science and food & beverage sectors

Large, fast growing and untapped total addressable market

Portfolio of software and technological end-to-end solutions for the digital supply chain



Long-term, trusted and blue-chip **customer relationships** driven by **one-stop-shop experience** and **tailored solutions** 



Multiple organic growth vectors addressing digitalisation & sustainability megatrends



Proven acquisition platform to supplement organic growth



Strong growth, margin expansion and scalability



Experienced, founder-led management team with vision and proven track record of success

# CLEAR LEADER IN LIFE SCIENCE TRACK & TRACE AND GROWING PRESENCE IN INSPECTION



© 2021 Antares Vision

#### HORIZONTAL INTEGRATION & COMPLETE OFFERING BEING ANTARES VISION KEY COMPETITIVE ADVANTAGE

#### GLOBAL LEADER IN LIFE SCIENCE TRACK & TRACE...

#### 2018A T&T LIFE SCIENCE MARKET SHARE <sup>(1)</sup>



Sources: Company Information, Markets & Markets, UCIMA (MECS – Centro Studi Ucima) Notes


- 1. Elaboration on data from Markets & Markets. Market share refers to a group comprising the main companies active in the track & trace market for the life science sector
- 2. Elaboration on data from Ucima (MECS Centro Studi Ucima) and Company Information

#### ... WITH INCREASING PRESENCE IN INSPECTION

2018A INSPECTION MARKET SHARE (2)

LARGE, FAST GROWING AND UNTAPPED TOTAL ADDRESSABLE MARKET





Sources: Markets & Markets, UCIMA (MECS – Centro Studi Ucima), Qualiket Research Notes

1. Elaboration on data from Markets & Markets (T&T), UCIMA (Inspection), Qualiket Research (Smart Data)

2. Due to rounding, the sum of the different numbers could slightly differ from the total


3. Original market value of €1.9 Bn, converted at average 2019 €/\$ exchange ratio, source BCE

 Includes other consumer and industrial T&T markets such as chemicals, components, raw materials, jewellery, transport & logistics and other

14

# END-TO-END SOLUTION WITH COMPLETE SOFTWARE SUITE FOR THE DIGITAL SUPPLY CHAIN





## DEEP RELATIONSHIPS WITH DIVERSIFIED & BLUE-CHIP CUSTOMER BASE

DELIVERING MISSION CRITICAL HEALTH & SAFETY SOLUTIONS: PROTECTING BRANDS, PEOPLE & PRODUCTS

#### >2,500 BLUE-CHIP CUSTOMERS (1)




2. Top 20 pharma companies by revenue in 2019 (source FiercePharma)

3. Top 20 food & beverage companies by revenue in 2020 (source Food Engineering)

## CLOSE CUSTOMER PROXIMITY & WORLDWIDE SERVICE CAPABILITIES






1. Workforce Pro-Forma at Group level

© 2021 Antares Vision

# CLEAR STRATEGY TO CREATE VALUE: UNTAPPED TANGIBLE ORGANIC GROWTH INITIATIVES ALONG THREE DIMENSIONS...



GROWTH ENABLED BY ENHANCED ORGANIZATIONAL STRUCTURE AND BUSINESS MODEL SCALABILITY




## ... SUPPORTED BY PROVEN AND DISCIPLINED ACQUISITION TRACK-RECORD AND CONCRETE PIPELINE OF M&A OPPORTUNITIES



#### ENABLES FURTHER GROWTH ACCELERATION, SYNERGISTIC VALUE CREATION & CROSS-SELLING


PROVEN ACQUISITION & PARTNERSHIP TRACK RECORD...

... WITH STRONG & CONCRETE PIPELINE OF OPPORTUNITIES



### STRONG GROWTH, MARGIN EXPANSION AND SCALABILITY





20

- 3. Gross margin defined as (Revenues COGS) / Revenues
- 4. Calculated on the basis of Antares Vision Spa ITA GAAP revenues per customer over 2015A-20A period, and based on customers retained as % of prior year revenue


investments in Real Estate, M&A and IFRS16 impact

6. Average 2018-2020 Recurring FCF Conversion, calculated as (EBITDA - Recurring Capex) / EBITDA

## EXPERIENCED FOUNDER-LED MANAGEMENT TEAM WITH VISION AND PROVEN TRACK-RECORD OF SUCCESS



EMPOWERED MANAGEMENT TEAM - STRONG TALENT POOL - FOCUS ON CSR/ESG








Section 3

## **MARKET & COMPETITION**

### OUR MARKETS TODAY: LARGE, RESILIENT AND GROWING





Sources: Euromonitor International Ltd, Passport Data Extracted February 2021 Notes

- 1. Pharmaceutical Production (Turnover MSP), y-o-y exchange rates, current prices
- 2. Medical and Surgical Equipment Production (Turnover MSP), ), y-o-y exchange rates, current prices as per "Medical Devices" definition
- 3. Food Production (Turnover MSP), y-o-y exchange rates, current prices
- 4. Beverages Production (Turnover MSP), y-o-y exchange rates, current prices
- 5. Home Care (retail value MSP), y-o-y exchange rates, current prices


6. Beauty and Personal Care (retail value MSP), y-o-y exchange rates, current prices, as per "Personal Care" definition 7. GDP, YoY exchange rates, current prices

8. Calculated as weighted average of the following industries in the reference periods: Pharmaceutical Production (Turnover MSP); Medical and Surgical Equipment Production (Turnover MSP), as per "Medical Devices" definition; Food Production (Turnover MSP); Beverages Production (Turnover MSP); Home Care (retail value MSP); Beauty and Personal Care (retail value MSP), as per "Personal Care" definition


© 2021 Antares Vision

## AT THE NEXUS OF A STRUCTURAL SHIFT TOWARDS SUPPLY CHAIN DIGITALIZATION, SUSTAINABILITY & TRUSTPARENCY®










Sources: Markets & Markets Notes

- 1. Due to rounding, the sum of the different numbers could slightly differ from the total
- Includes other consumer and industrial T&T markets such as chemicals, components, raw materials, jewellery, transport & logistics and other
- 3. As of December 2020

### **TRACK & TRACE: MARKET SIZE AND STRUCTURE**







 Global Track & Trace market growth supported by strong performance of all end-markets


 F&B expected to switch to Life Science model (single packaging tracking), representing an area of further growth opportunity



- Life science outgrowing other segments supported by:
   Regulatory requirements for traceability of
  - pharmaceutical products
  - Upside from over-the-counter (OTC) market regulation
  - Increasing significance of the Asian market

## TRACK & TRACE: GROWTH BY END-MARKETS AND GEOGRAPHIES





#### FORMAL ADOPTION OF SERIALIZATION AND AGGREGATION REGULATION IN MANY MARKETS IS EXPECTED TO DRIVE SIGNIFICANT GROWTH

Sources: Markets & Markets Notes 1. Due to rounding, the sum of the different numbers could slightly differ from the total

27


# REGULATION PAVING THE WAY FOR ALL-TIME HIGH T&T PENETRATION IN PHARMACEUTICALS



75% PRESCRIPTION DRUGS'

#### RAPID EVOLUTION AHEAD OF US, WITH STILL EMBRYONIC INDUSTRIAL MARKET

#### PRESCRIPTION DRUGS' REGULATION STATUS



Sources: Company Information, Businesswire, Management Elaboration on GS1 Data, on Markets & Markets Data and Company Information Notes


1. Further implementation of Serialization in Ukraine and UAE, Aggregation in Bahrain, full regulation in Ethiopia

2. Further implementation of full regulation in Malaysia and Qatar (on primary packaging)



#### COUNTRIES WITH DEVELOPED PHARMA REGULATIONS TEND TO EXPAND TRACK & TRACE REGULATIONS TO OTHER INDUSTRIES

- Russia already introduced serialization for Tobacco and Alcoholic Beverages
- Introducing progressively serialization in several other markets: milk, mineral water, soft drinks, etc.
- Will be the pilot country in the world for massive serialization provided by law
- **Turkey: pilot country for pharmaceutical serialization** since 2010
- Brazil, India and others are introducing similar regulations
- China introduced the law to serialize Food & Beverage within the program Made in China 2025
- USA: the FDA launched the initiative The New Era of Smarter Food Safety on 13<sup>th</sup> July 2020



Sources: Management Elaboration on GS1 Data


#### Notes

1. Tobacco cigarettes already implemented in July 2020, tobacco alternative products to be implemented by July 2021

2. Tobacco cigarettes already implemented in 2019, tobacco alternative products to be implemented by 2024

## **INSPECTION: SUMMARY OVERVIEW OF MARKET DYNAMICS**







 ✓ Global inspection market is outpacing the global packaging machinery market with a + 2.3% CAGR 2020A-22E and it is expected to reach €2.1 Bn market size by 2022E




Global inspection market growth is driven by attractive Life
 Science and Food & Beverage markets

✓ Growth driven by increased use of technological inspection solutions

Sources: UCIMA (MECS – Centro Studi Ucima) Notes 1. Original market value converted at average 2020 €/\$ exchange ratio, source BCE

### **INSPECTION MARKET: MARKET BREAKDOWN BY END-MARKET**







 Inspection market more concentrated by end-market
 Life Science and Food & Beverage – core end-markets for Antares Vision – represent the two main segments




 Life Science and Food & Beverage growth driven by the need to comply with strict industry quality standards and focus on end to end visibility and transparency


Sources: UCIMA (MECS – Centro Studi Ucima) Notes

1. Original market value converted at average 2020 €/\$ exchange ratio, source BCE 2. Includes Cosmetics, Chemicals, Tobacco, Tissue, Building materials and other

## **INSPECTION: GROWTH BY END-MARKETS AND GEOGRAPHIES**







✓ With a 6.0% CAGR 2020-25, Europe is expected to outgrow the

other markets and to reach the same market size as APAC and

FOOD & BEVERAGE INSPECTION BY GEOGRAPHY



✓ Life Science inspection continues to be a resilient market

Europe and APAC represent the main markets

Sources: UCIMA (MECS – Centro Studi Ucima) Notes:

1. Due to rounding the sum of the different numbers could slightly differ from total 2. Original market value converted at average 2019 €/\$ exchange ratio, source BCE

3. Original market value converted at average 2020 €/\$ exchange ratio, source BCE

North America by 2025E

### SMART DATA: SUMMARY OVERVIEW OF MARKET DYNAMICS




|                | OPTIMIZING<br>OPERATIONAL<br>EFFICIENCY<br>AND CUSTOMER<br>ENGAGEMENT | <ul> <li>Ability to unify and manage large amounts of data</li> <li>Helps to optimize companies' performance and enhance customer engagement</li> <li>Data monitoring drives security, commercial approach and predictive maintenance/problem solving</li> </ul>   |
|----------------|---|--|
| GROWTH DRIVERS | SMART DATA<br>VS. BIG DATA  | <ul> <li>"Smart Data" represents the evolution of more established "Big Data"</li> <li>Helps to rationalize, collect and optimize large amounts of gathered data in order to improve consumer engagement</li> <li>Further advantage in Smart Data in terms of financial, technical and HR costs</li> </ul> |
|                | INCREASING AWARENESS<br>OF IOT DEVICES                                | <ul> <li>Increasing awareness and utilization of "Internet of Things" devices driving growth in Smart Data</li> <li>Several IoT applications require Smart Data inputs today</li> <li>Increasing opportunities to offer SaaS for the management of data</li> </ul>   |
| OPPORTUNITIES  | DEVELOPMENT THROUGH     ARTIFICIAL INTELLIGENCE                       | <ul> <li>Artificial Intelligence (and Machine Learning) creates <b>new opportunities</b> for Smart Data Management</li> <li>Helps in <b>easing</b> and <b>automating screening and filtering process</b> within gathered Big Data</li> </ul>   |

GROWTH DRIVEN BY INCREASING RECOGNIZED ADVANTAGES FROM SMART DATA APPLICATION AND POTENTIAL FROM INTEGRATION WITH ARTIFICIAL INTELLIGENCE


## SMART DATA: GROWTH BY END-MARKETS AND GEOGRAPHIES





 Market led by pharmaceuticals and medical devices with expansion to other businesses by 2025E

✓ Smart Data Management at the focal point of a digital supply chain





Developed markets (North America and Europe) historically the main markets, with **APAC expected to catch up by 2025E** driven by increased **focus on efficiency and quality** 


#### Sources: Qualiket Research Notes

1. Due to rounding, the sum of the different numbers could slightly differ from the total

#### COUNTERFEIT MARKET: PHARMACEUTICAL DEEP DIVE







# COMPETITIVE ARENA MAPPING: ANTARES VISION'S COMPLETE OFFERING



|                    |               |              | TRACK & TRACE |              |              |                      |              | INSPECTION   |              |           |                       |                       |               |
|--------------------|---------------|--------------|---------------|--------------|--------------|----------------------|--------------|--------------|--------------|-----------|-----------------------|-----------------------|---------------|
|                    |               | PHARMA       | MEDICAL DEV.  | FOOD         | BEVERAGES    | HOME CARE PERS. CARE | PHARMA       | MEDICAL DEV. | FOOD         | BEVERAGES | HOME CARE             | PERS. CARE            | SMART<br>DATA |
|                    | ANTARESVISION | $\checkmark$ | $\checkmark$  | ✓            | ✓            | $\checkmark$         | ✓            | ✓            | $\checkmark$ | ✓         | <ul> <li>✓</li> </ul> | <ul> <li>✓</li> </ul> | $\checkmark$  |
| DIRECT COMPETITORS | Player 2      | $\checkmark$ |               |              |              |                      | $\checkmark$ |              |              |           |                       |                       |               |
|                    | Player 3      | ✓            | $\checkmark$  | $\checkmark$ | $\checkmark$ |                      | $\checkmark$ | $\checkmark$ |              |           |                       |                       | $\checkmark$  |
|                    | Player 4      | $\checkmark$ | $\checkmark$  | $\checkmark$ | $\checkmark$ | $\checkmark$         |              |              |              |           |                       |                       | $\checkmark$  |
|                    | Player 5      | $\checkmark$ |               |              |              |                      | ✓            |              |              |           |                       |                       |               |
|                    | Player 6      |              |               |              |              |                      | $\checkmark$ |              |              |           |                       |                       |               |
|                    | Player 7      | ✓            |               |              |              |                      | ✓            |              |              |           |                       |                       | $\checkmark$  |
|                    | Player 8      |              |               |              |              |                      | $\checkmark$ |              |              |           |                       |                       |               |
|                    | Player 9      | $\checkmark$ |               |              |              |                      |              |              |              |           |                       |                       |               |
|                    | Player 10     | $\checkmark$ |               | $\checkmark$ | $\checkmark$ |                      |              |              | ~            |           |                       |                       |               |
|                    | Player 11     | $\checkmark$ |               |              |              |                      |              |              |              |           |                       |                       | $\checkmark$  |
|                    | Player 12     |              |               |              |              |                      |              |              | ~            | ~         | ~                     |                       |               |


#### ANTARES VISION IS EXPANDING ITS OFFERING OUTSIDE THE PHARMACEUTICAL INDUSTRY ACHIEVING A DIFFERENTIATED POSITIONING AND MORE COMPLETE OFFERING COMPARED TO MOST OF ITS COMPETITORS

36

### **CLEAR LEADER IN LIFE SCIENCE TRACK & TRACE AND GROWING** PRESENCE IN INSPECTION

active in the track & trace market for the life science sector





© 2021 Antares Vision

# ANTARES VISION IS WELL POSITIONED WITH HORIZONTAL INTEGRATION WITHIN T&T, INSPECTION AND SMART DATA



|               | TRACK & TRACE         |                 |                | INSPECTION            |              | SMART DATA   |                   |              |
|---------------|-----------------------|-----------------|----------------|-----------------------|--------------|--------------|-------------------|--------------|
|               | STANDALONE<br>MACHINE | INTEGRATION KIT | PLANT SOFTWARE | CORPORATE<br>SOFTWARE | MACHINE      | SYSTEMS      | MANUFACTURING 4.0 | SUPPLY CHAIN |
| ANTARESVISION | $\checkmark$          | $\checkmark$    | $\checkmark$   | $\checkmark$          | $\checkmark$ | $\checkmark$ | $\checkmark$      | $\checkmark$ |
| Player 2      | ✓                     | $\checkmark$    | $\checkmark$   | $\checkmark$          | $\checkmark$ |              | ✓                 |              |
| Player 3      | $\checkmark$          | $\checkmark$    | $\checkmark$   | $\checkmark$          |              | $\checkmark$ |                   | $\checkmark$ |
| Player 4      | $\checkmark$          | $\checkmark$    | ✓              | ✓                     |              |              |                   | ✓            |
| Player 5      | $\checkmark$          | $\checkmark$    | $\checkmark$   |                       |              | $\checkmark$ |                   |              |
| Player 6      |                       |                 |                |                       | ✓            |              |                   |              |
| Player 7      |                       | $\checkmark$    | ✓              |                       |              | ✓            | $\checkmark$      |              |
| Player 8      |                       |                 |                |                       | ✓            |              |                   |              |
| Player 9      | $\checkmark$          | $\checkmark$    |                |                       |              |              |                   |              |
| Player 10     | $\checkmark$          | ✓               | ✓              |                       |              | / /          | X                 |              |
| Player 11     |                       |                 |                | ✓                     |              | / //         | <u> </u>          | ✓            |
| Player 12     |                       |                 |                |                       | ✓            | $\checkmark$ |                   |              |

#### ANTARES VISION OFFERS A DISTINCTIVE "ONE-STOP-SHOP" SOLUTION WITH PORTFOLIO OF PRODUCTS AND SERVICES WHICH COVER THE ENTIRE PRODUCT LIFECYCLE

### **KEY MARKET TAKEAWAYS**



#### LARGE, FAST-GROWING AND UNTAPPED TOTAL ADDRESSABLE MARKET, WITH SIGNIFICANT OPPORTUNITIES








Section 4

### **SOLUTIONS OFFERING**


# COMPLETE SOFTWARE-ENABLED PLATFORM ACROSS TRACK & TRACE, INSPECTION, SMART DATA AND SERVICES





## 1) TRACK & TRACE: INTRODUCTION & KEY HIGHLIGHTS





Sources: Company Information, Markets & Markets Notes 1. Based on delivered Track & Trace lines as of December 2020 2. As of December 2019

42

## 1 TRACK & TRACE: SOLUTIONS MIX




#### COMPLETE SUITE OF SERIALIZATION, AGGREGATION AND SOFTWARE SOLUTIONS

| MACHINE                        |   | DESCRIPTION  |  |  |  |  |
|--------------------------------|---|--|--|--|--|--|
|                                | SERIALIZATION<br>SOLUTIONS  | <ul> <li>Assigns a predetermined unique coding type to each product (saleable unit)</li> <li>Allows the product to be identified and virtually tracked and traced across the value chain</li> <li>Monitors route to end-consumer (especially with prescription drugs)</li> <li>Safeguard against product counterfeiting or thefts</li> </ul> |  |  |  |  |
| HARDWARE                       | <ul> <li>AGGREGATION<br/>SOLUTIONS</li> <li>Allows identifying codes application at secondary and tertiary packaging levels</li> <li>Creates a digital relationship between case serial numbers and those of saleable units</li> <li>Allows packaging receivers (e.g. wholesalers, hospitals) to view the content of the whole bundle by scanning just</li> </ul>   |  |  |  |  |  |
| <b>کے پ</b><br>چھڑ<br>SOFTWARE | <ul> <li>TRACKING, TRACING,<br/>&amp; REPORTING<br/>SOLUTIONS</li> <li>Used to support hardware process and track coded products across the value chain</li> <li>Obtained data has a large variety of uses, such as:         <ul> <li>Gathering commercial insights on consumers habits</li> <li>Analyzing pharmacies and consumer needs for (mostly) prescription drugs</li> <li>Tracing counterfeiting and tracking eventual drug thefts</li> <li>Ensuring supply chain traceability</li> </ul> </li> </ul> |  |  |  |  |  |



Sources: Company Information











## 1 DEEP DIVE ON TRACK & TRACE SYSTEMS





### ANTARES VISION MILESTONES IN TRACK & TRACE – PROVEN RECORD ① OF INDUSTRY FIRSTS





## 2 INSPECTION: INTRODUCTION & KEY HIGHLIGHTS







| INSPECTION SOLUTIONS |  | DESCRIPTION  |  |  |  |
|----------------------|--|--|--|--|--|
| -A-A-o               | INSPECTION MACHINE<br>(STANDALONE)     | <ul> <li>TCI Visual Inspection: fully automatic standalone machine designed to inspect pharmaceutical capsules and tablets</li> <li>VRI - Visual Rotating Inspector: Visual Inspection and Container closure integrity test of parenteral/sterile products</li> </ul>  |  |  |  |
| LIFE SCIENCE         | INSPECTION SYSTEMS                     | <ul> <li>Inspection system for product integrity control: Blister Filling Control, Foreign Detection, product aesthetic control</li> <li>Inspection system for packaging control: verification of bar code, OCR/OCV (e.g. expiration date, batch number), packaging closure, leaflet presence, presence and positioning of labels and seals</li> </ul> |  |  |  |
| FOOD &<br>BEVERAGE   | INSPECTION SYSTEMS<br>(LEAK DETECTION) | <ul> <li>Laser spectroscopy: detection of holes and micro-holes, pressure measurement, vacuum measurement, escaping gas detection</li> <li>"Squeezer" based: detection of holes and micro-holes</li> </ul>   |  |  |  |












Sources: Company Information

### 2 INSPECTION SOLUTIONS FOR LIFE SCIENCE (STERILE PRODUCTS)





#### QUALITY CONTROL TO GUARANTEE:

#### **Product Integrity**

-∿-∿-

- Product inspection
- Cosmetic container inspection
- Container closure integrity check

#### **Packaging Control**

- Barcode / Datamatrix inspection
- Product orientation control
- Leaflet and flaps check
- Seal inspection
- Label inspection
- Printing control

### (2) INSPECTION: CASE STUDIES ON INNOVATION



#### AUTOMATIC QUALITY CONTROL SYSTEM - ROBO QCS



- Robo QCS is an in-line automatic system to **sample and test product** quality
- Ideal for **dynamic and continuous optimization** of the line efficiency and performance monitoring
- Through a continuous and automated sampling and non-destructive product analysis, it ensures products' highest quality and line performance monitoring

#### LEAK DETECTION SYSTEM – LDS

- **LDS** is an **in-line seal inspection system**, designed to detect leakage in food packaging
- Ability to perform **non-destructive control** on 100% of production, directly in line, ensuring **food safety** and **quality** of the final product

#### ULTRA-FILTERED MILK BRAND

- FT System is capable of **fully inspecting**:
  - ✓ Quality of products filled in aseptic lines
  - ✓ Fill level
  - ✓ Caps closure and leakage
  - ✓ Removal torque and volume





#### ITALIAN PASTA MAKER


- LDS is the only system based on the innovative laser spectroscopy technology, that detects holes and microleakage on packaged food products
- The company has **12 LDS machines** installed in Italy and **4 in the US**



### 2 ANTARES VISION MILESTONES IN INSPECTION



CONTINUED STRATEGIC



### 3) SMART DATA: INTRODUCTION & KEY HIGHLIGHTS






## 3) SMART DATA: SOLUTIONS MIX

2. Assets acquired






© 2021 Antares Vision


### END TO END SOLUTIONS FOR THE DIGITAL SUPPLY CHAIN WITH IN-(3) HOUSE NATIVE BORNE SOFTWARE SUITE ENRICHED THROUGH M&A





### RFXCEL AT-A-GLANCE: COMPLETE SUPPLY CHAIN VISIBILITY AND 3 SECURITY





1. Based on rfXcel reporting fiscal year ending March 2018-20

54

### **SERVICES: INTRODUCTION & KEY HIGHLIGHTS**






**KEY** 

Sources: Company Information

1. Customer service management

Notes

HIGHLIGHTS




3. Clients' legal entities related to the same Group considered as single client

### 4 SERVICES: SOLUTIONS MIX



MAINTENANCE SUPPLY OFFERING ENRICHED BY TECHNICAL CONSULTING, AD-HOC SOFTWARE DEVELOPMENT/MODIFICATION AND CLIENT EMPLOYEES TRAINING



Sources: Company Information

### CASE STUDIES: TRACK-RECORD OF WINNING



|                                  | #1   | #2  | #3   |  |
|----------------------------------|--|---|--|--|
| CUSTOMER                         | US-based biopharma<br>company  | US-based healthcare company   | World leader company<br>in personal care   |  |
| COUNTRY                          |  |   |  |  |
| YEAR/VALUE                       | 2019/ €1.2 Mn  | 2020-2021/ €650k  | Multiyear  |  |
| PROJECT<br>DESCRIPTION           | <ul> <li>Visual inspection of low-filled vials</li> <li>CCIT with vacuum</li> <li>Laser print and check</li> <li>UV inkjet 2D code, with serialization/verification</li> </ul> | <ul> <li>Visual inspection of large volume glass bottles for infusion</li> <li>100 to 1000ml high speed line</li> <li>Use of HSGA for liquid products (presence of nitrogen overlay)</li> </ul> | <ul> <li>Under implementation</li> <li>Track &amp; trace L2 – L4 (line, plant, company)</li> </ul> |  |
| THE ANTARES VISION<br>DIFFERENCE | <ul> <li>✓ Customised and flexible offeri</li> <li>✓ Co-development with custome</li> </ul>  | $\sim$ 360° coverage with customer provimity and on the   |  |  |

57



© 2021 Antares Vision








Section 5

### **FOCUS ON INNOVATION**

### WE CONTINUE TO REDEFINE THE FUTURE OF OUR SECTOR







14%





GLOBAL SERIALIZATION SYSTEMS & CERTIFIED SOLUTIONS IN EUROPE

SOFTWARE AS % OF TOTAL 2020PF REVENUES<sup>(1)</sup>

WORKFORCE IN R&D<sup>(2)</sup>

26%





#### **INNOVATION DNA & FOCUS ON EMERGING TECHNOLOGIES**



AI, ARTIFICIAL VISION & SENSORS



BLOCKCHAIN TECHNOLOGY



IoT & CLOUD



COMPRESSION & STORAGE



AUTHENTICATION




CONNECTIVITY

Sources: Company Information Notes 1. 2020 Pro-Forma for the acquisition of rfXcel 2. Workforce Pro-Forma at Group level

### **INNOVATION TRACK-RECORD, STRATEGY AND ROADMAP**





### EMPOWERED BY NEW INNOVATION CENTER



#### THE FUTURE IS HERE

#### **INNOVATION CENTER AT-A-GLANCE**


- Antares Vision Innovation Center (founded in 2018) opened in October 2020 a new branch at the CSMT (Multisectorial and Technological Service Center) in Brescia
- Promotes research and technological development
- Facilitates networking, information sharing and synergies between startups, university departments, research Institutes and corporates

## PARTNERSHIPS WITH...AND WITH INTERNATIONALLEADING UNIVERSITIES...RESEARCH CENTERS

AS PART OF ITS **DIGITAL EVOLUTION STRATEGY**, ANTARES VISION HAS ACTIVATED SEVERAL COOPERATIONS & PARTNERSHIPS WITH THE SOME OF THE MAIN **UNIVERSITIES** AND **RESEARCH CENTERS**.

THE OBJECTIVE IS TO DEVELOP AND ENHANCE THE CAPABILITIES WITHIN THE MOST **ADVANCED TECHNOLOGIES** IN TERMS OF **IMAGING**, **INSPECTION**, AND **PROCESS MONITORING**, INCLUDING ALSO **ARTIFICIAL INTELLIGENCE** 

#### FOCUS ON EMERGING HIGH GROWTH TECHNOLOGIES






#### SOFTWARE, DIGITAL & SMART DATA SOLUTIONS DEVELOPED IN-HOUSE... ...WITH M&A AS A LEVER TO ENHANCE KNOW-HOW AND OFFERING SMART DATA MANAGEMENT SOLUTIONS TO MAXIMIZE AND ENHANCE ATS - SOFTWARE ECOSYSTEM TO MANAGE SERIAL IZATION FROM SEP PERFORMANCES ST 🔊 LEVEL 1 TO LEVEL 3, FROM EQUIPMENT TO CORPORATE LEVEL ATS-2011-2019 Software **CONSULTANCY** FOR THE PROCESSES OF SERIALISATION AND 2015 **WTS** TRACEABILITY WTS - SOFTWARE FOR WAREHOUSE MANAGEMENT BASED ON SERIALIZATION 000 DEC PROJECTS AND SOLUTIONS BASED ON ARTIFICIAL INTELLIGENCE FOR 2019 PROCESS AUTOMATION AND DECISION SUPPORT SOFTWARE ECOSYSTEM TO MANAGE THE DATA STORAGE AND **ATSFOUR** 2018 **INFORMATION FLOW FROM CORPORATE TO AUTHORITIES LEVEL** APR MULTI-TENANT LOW COST CLOUD SOLUTION FOR SMALL-MEDIUM **TRADETICITY** 2020 **ENTERPRISES** INTERCONNECTABLE WITH THIRD PARTIED T&T LINES SOFTWARE PLATFORM FOR DIGITALIZATION OF SUPPLY CHAIN FROM RAW MATERIAL TO THE END USER TRACK 2019 SINGLE TENANT CLOUD SOLUTION DEVELOPED IN PARTNERSHIP WITH OFFERS TRACEABILITY, PRODUCTS LIFE-CYCLE TRANSPARENCY. **MYWAY** NOV MICROSOFT AZURE BRAND PROTECTION AND AUTHENTICATION. CUSTOMER EXPERIENCE 2020 AND SUSTAINABILITY ADVANCED SOLUTION FOR TRACEABLITY FROM PRODUCTION TO **HOSPITALS** SOFTWARE AS A SERVICE TRACK & TRACE SOLUTIONS PROVIDING DASHBOARD FOR A DATA INTELLIGENCE LANDSCAPE IN PRODUCTION END-TO-END SUPPLY CHAIN VISIBILITY **FEB** rfxcel **AVIONICS** 2019 ALLOWS TO IMPROVE PERFORMANCES WITH A DATA-DRIVEN MINDSET 2021 COMPLIANCE, SERIALIZATION, TRACEABILITY AND MONITORING AND WITH THE EMPOWERMENT OF ARTIFICIAL INTELLIGENCE L5 PLATFORM FOR AUTHORITIES HUB **IN-HOUSE DEVELOPMENTS** ACQUIRED PLATFORMS

Sources: Company Information Notes 1. Minority stake 2. Assets acquired


# REINFORCED R&D HEADCOUNT THROUGH ORGANIC AND INORGANIC EXPANSION ENABLING INNOVATION





### INNOVATION CASE STUDIES: ARTIFICIAL INTELLIGENCE







#### THE LYO-CHECK PROJECT AT-A-GLANCE

ANTARESVISION LYO

#### DISRUPTIVE INNOVATION IN THE VISUAL INSPECTION OF LYOPHILIZED PHARMACEUTICAL PRODUCTS

The LYO-CHECK project creates an automatic industrial machine for the **visual inspection** of **lyophilized pharmaceutical** preparations **intended for injections**. It is based on two main technologies:

- Innovative Vision architecture (dedicated software and optical layout) for inspection of foreign matters on the product or cosmetic/functional defects on the primary container
- Head Space Gas Analysis (HGSA technology) for sterility testing through container closure integrity





Packaging & Handling Category



European Union Funding Received <sup>(1)</sup>

Sources: Company Information Notes

Containers per

Minute

(High Capacity)

1. The LYO-CHECK project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 738523

**Cosmetic Inspection** 

with Detection

of Defects

66

**LOWER PROCESS** 

**COST** COMPARED TO

MANUAL INSPECTION

### **INNOVATION CASE STUDIES: NEW HEALTHCARE APPLICATIONS**



#### FROM TRACEABILITY OF PRODUCTS TO TRACEABILITY OF PEOPLE

#### COVID-19 FREE FLOW PORTAL- TRACK MY HEALTH

- TRACK MY HEALTH is an integrated and scalable solution
- Automatic controls for the entry/exit of people from public spaces and automatically generating alarm signals in case of abnormal behaviour
- Set of dedicated, tailor-made, modular, scalable and integrated hardware/software solutions which are compatible with existing surveillance and control systems

#### **KEY BENEFITS:**

- Control of body temperature
- Mask control
- ✓ People counting
- Access control with body temperature check
- Queuing control
- Distancing control
- Remote and on-site management platform
- Enabled for artificial intelligence

#### HEALTHCARE 4.0 – SMART WARD PLATFORM

- Define new organizational standards and services to patients in the departments of the hospitals with an intelligent, high-tech and flexible platform (SMART WARD PLATFORM) cantered on individual patient well-being
- Independently manage all patient assistance-related functions and interfaced with any hospital ERP for the exchange of key information


#### **KEY BENEFITS:**

- ✓ Patient centric system
- Prevents operators' errors
- Medicine and medical device waste optimization
- Inventory information always available including EXP date
- Medicine movements between and within wards
- All and full traceability, till unit dose serialization
- Increase security for medicine dispensing



#### **R&D AWARDS AND RECOGNITION**







ANTARESVISION Our technology, your safety.


Section 6

### **CUSTOMER BASE & CROSS-SELL**

### GROWING AND LOYAL CUSTOMER BASE...



#### RAPIDLY EXPANDING CUSTOMER BASE AND LONG LASTING RELATIONSHIPS WITH KEY ACCOUNTS




### ...WITH HIGHLY STICKY AND RECURRING PROFILE



#### RETAINED CUSTOMERS GENERATE ~95-99% OF REVENUE

CUSTOMER RETENTION

% OF PRIOR YEAR REVENUES (1)





**CO-DEVELOPMENT OF TAILORED SOLUTIONS** 



**GLOBAL FOOTPRINT &** CUSTOMER PROXIMITY

#### Sources: Company Information

#### Notes


1. Calculated on the basis of Antares Vision Spa ITA GAAP revenues per customer over 2015A-20A period, and based on customers retained as % of prior year revenue 2. Calculated as the ratio of the revenue attributed to customers lost during the year compared to total

revenues of the previous year

© 2021 Antares Vision


# RAPIDLY GROWING INSTALLED BASE ACCELERATING LIFE-CYCLE SERVICE PENETRATION...





# ...WITH COMPLETE SOLUTION UNLOCKING LARGE CROSS-SELL OPPORTUNITY






# **CROSS-SELLING CASE STUDIES**



# LEVERAGING COMPLETE OFFERING AND PENETRATING GROWING INSTALLED BASE ACROSS BOTH T&T AND INSPECTION



# **TENDER PROCESS AND CONTRACT STRUCTURE**



# OVERVIEW OF LIFE SCIENCE BUYING PROCESS

## 1 TENDER

- Projects initiated by customer tenders for solutions that meet specific technical and functional needs
- AV competes with other suppliers on technical and quotation parameters

DEFINITION OF USER REQUIREMENT SPECIFICATION (URS)

IDENTIFICATION AND INVITATION OF SUPPLIERS QUALIFIED THAT RESPOND TO URS

SALES FORCE EVALUATION OF CUSTOMERS' URS WITH PRELIMINARY STUDIES

SALES FORCE ELABORATION AND PRESENTATION OF THE COMMERCIAL OFFER

NEGOTIATION PHASE ON TECHNICAL AND QUOTATION ASPECTS

CUSTOMER ORDER (NORMALLY PREPAYMENT OF C. 30-40% OF THE PROJECT VALUE)

IMPLEMENTATION PHASE

## 2 FRAMEWORK / GENERAL TERMS AGREEMENT (NO EXCLUSIVITY)

- Some customers rely on a short list of suppliers (c. 2-3)
  - Proximity to the customer is a competitive advantage



## **3** FRAMEWORK AGREEMENTS (EXCLUSIVITY)

- With some customers, AV has an exclusive relationship and does not compete with other suppliers given exclusivity
- Exclusive framework agreements basically include the definition of:

GENERAL PLANNING OF THE REALIZATION AND IMPLEMENTATION OF THE SOLUTIONS SUPPLY CONDITIONS, LEAVING THE ISSUE OF SPECIFIC ORDERS TO THE INDIVIDUAL LOCAL UNITS






Section 7

# **BUSINESS MODEL & OPERATIONS**

# ASSET LIGHT AND AGILE BUSINESS MODEL...





ASSET LIGHT, AGILE AND HIGHLY CASH GENERATIVE BUSINESS MODEL FOCUSED ON DESIGN, INNOVATION, SOFTWARE AND SERVICES

Sources: Company Information



© 2021 Antares Vision

## IN-HOUSE FOCUS ON VALUE-ADD PROCESSES SUPPORTING MINIMAL CAPEX REQUIREMENTS


|                   |  |   | OUTSOURCING      | PROCESS VALUE-ADD               |
|-------------------|--|---|------------------|---------------------------------|
|                   | MONITORING,<br>IREMENTS ANALYSIS<br>OMMERCIALIZATION | <ul> <li>Identification of market opportunities and customer needs</li> <li>Global presence and proximity to customers</li> <li>Constant collaboration and co-creation with customers</li> </ul>  |                  |                                 |
|                   | DESIGNING  | <ul> <li>Development and definition of all the software and hardware aspects of the solutions to be implemented as defined in the User Requirements Specification</li> <li>100% managed in-house leveraging on a highly skilled team</li> </ul>             |                  |                                 |
| ANTARESVISION     | REALIZATION  | <ul> <li>Assembly of mechanical and metal components (<u>outsourced</u>) A</li> <li>Partial production of critical value-add components and integration of critical electrical, electronic and optical/inspection components (<u>in-house</u>) B</li> </ul> |                  |                                 |
| BUSINESS<br>MODEL | SHIPPING &<br>COMMISIONING                           | <ul> <li>Delivery and installation (including all software systems) at customers production sites of the solutions realized</li> <li>Verification of the correct functioning of the solutions provided</li> </ul>   |                  |                                 |
|                   | MAINTENANCE  | <ul> <li>Wide range of valuable after-sales services provided to customers, accessible both on-site and remotely</li> <li>Remote assistance, maintenance, spare parts and training programs</li> </ul>  |                  |                                 |
|                   | RESEARCH &<br>DEVELOPMENT                            | <ul> <li>Improve and expand the solutions and technologies offered</li> <li>Strong focus on innovation to maintain the technological leadership and to provide customers with innovative and high-tech solutions</li> </ul>                                 |                  |                                 |
|                   |  |   | High Outsourcing | High Value-Add<br>Low Value-Add |

78

# **DESIGNING AND REALIZATION**



## DESIGNING AND REALIZATION OF CRITICAL AND HIGH VALUE-ADD COMPONENTS CARRIED



# STRONG MANUFACTURING BASE AND SUPPLY CHAIN



## 11 PRODUCTION FACILITIES WORLDWIDE...



| COMPANY                         | COUNTRY | SURFACE<br>(SQM)         |
|---------------------------------|---------|--------------------------|
| Antares<br>Vision SpA           |         | c. 4,117 sqm             |
| Antares<br>Vision SpA           |         | c. 750 sqm               |
| Antares<br>Vision SpA           |         | c. 3,770 sqm             |
| FT System<br>Srl                |         | c. 2,932 sqm             |
| FT System<br>Srl <sup>(4)</sup> |         | c. 292 sqm               |
| Convel<br>Srl                   |         | c. 804 sqm <sup>(3</sup> |
| Pen-Tec                         |         | c. 630 sqm               |
| Antares<br>Vision Inc           |         | c. 498 sqm               |
| Antares<br>Vision Brasil        | )       | c. 1,126 sqm             |
| Imago<br>Tech. GmbH             |         | c. 1,417 sqm             |
| Applied<br>Vision               |         | c. 64,318 sqm            |

### ...AND SOLID SUPPLIERS' NETWORK


|   | SUPPLIER C                          | OUNTRY     | CATEGORY                                 |
|---|-------------------------------------|------------|--|
| 8 | stake in Jan-2019<br>Siempharma Srl |            | Hardware<br>Provider                     |
| 8 | Supplier 2                          | $\bigcirc$ | Hardware<br>Provider                     |
| 8 | Supplier 3                          | $\bigcirc$ | Machines Installation<br>and Commissions |
| _ | Supplier 4                          | $\bigcirc$ | Hardware<br>Provider                     |
| _ | Supplier 5                          |            | Software<br>Services                     |

IN ORDER TO OPTIMIZE THE PRODUCTION FLOW, ANTARES VISION OUTSOURCES THE ASSEMBLY AND PRODUCTION OF MOST LOW VALUE-ADD COMPONENTS TO A STRONG NETWORK OF TRUSTED CONTRACTORS/SUPPLIERS

# ROUTE TO MARKET OVERVIEW




## ROUTE MARKET MODEL BASED ON DIRECT SALES FORCE AND PARTNERS (AGENCIES AND DISTRIBUTORS)



#### AV operates:

- Directly through a network of strategically located operating offices and the HQ
- Indirectly through a network of agents and qualified partners companies worldwide
- **Partner companies** (73% agencies, 27% distributors) mainly operate at **local level**, to serve Pharma brand manufacturers and CMOs
- Mostly operate also as **certified installers** of the issuer's solutions and systems
- Key accounts are managed by direct sales force that avail of local sales structure to manage the client globally
- **Customer proximity** is a key success factor in winning framework agreements

# 2 ROUTE TO MARKET – EXTRA LIFE SCIENCE



- ✓ AV operates:
  - Directly, leveraging a network of strategically located operating offices (subsidiaries) at Group Level, developing specific Extra-Life Science BUs with own sales force and technicians (specific industry knowledge)
  - ✓ **Indirectly** through a network of **agents** and **qualified partners** companies worldwide with whom AV has built long lasting relationships
- ✓ AV serves a wide array of customers: Food & Beverage brand owners, Cans/Glass producers and also OEMs
- ✓ Key accounts are managed by **direct sales force** that avail of local sales structure to manage the client globally

# CUSTOMER PROXIMITY STRATEGY



# STRONG SALES FORCE WITH A GLOBAL FOOTPRINT OPERATING BOTH DIRECTLY AND INDIRECTLY



#### Sources: Company Information

Notes

- 1. ME includes: Jordan, Lebanon, Israel, United Arab Emirates, Iran (dedicated partner), Pakistan, Bangladesh
- 2. Africa includes: North Africa, South Africa and Egypt
- 3. Subsidiaries and JV (partnership under finalization in 2021)

Covered


✓ To Be Covered From 2021 🗶 Not Covered

# SHIPPING AND COMMISSIONING




## LOGISTICS, DELIVERY AND INSTALLATION OF ANTARES VISION HARWARE/SOFTWARE SOLUTIONS

## DESCRIPTION



- The correct functioning of the solutions provided (Site Acceptance Test SAT), is tested through technicians who carry out the tests necessary to obtain from the customer the definitive confirmation that the solution and systems meet the specific requirements
- For purely software solutions, commissioning phase is carried out by installing them at the customer on premises or on cloud, in the case of multi-tenant software







## MARKETING STRATEGY PILLARS

#### MARKETING STRATEGIC OBJECTIVES 2021-2025

| OBJECTIVES |                    | DESCRIPTION  |
|------------|--------------------|--|
| 1          | BRAND<br>VALUE     | <ul> <li>Strengthen brand awareness on Life Science and diversification in target end-market (e.g. F&amp;B)</li> <li>Extending AV unique visual identity to new potential M&amp;A opportunities</li> <li>Gradual repositioning and extension from hardware to software and data</li> </ul> |
| 2          | SUPPORT SUPPORT    | <ul> <li>Market estimation, data analysis and intelligence to support sales strategy through:</li> <li>Internal market and competition intelligence improvement</li> <li>Analysis and studies with 3rd parties</li> </ul>  |
| 3          | LEAD<br>GENERATION | <ul> <li>Dedicated Information Campaign through development of customer profiling</li> <li>Programs of Lead generations and customer journey to sustain business development trough Marketing automation and CRM</li> </ul>  |


## APPROACH TO LEAD GENERATION



# CASE STUDY: LEAD GENERATION & BRAND DEVELOPMENT



# ANTARES VISION MARKETING SUSTAINED PRODUCT EXTENSION AND CROSS-SELLING WITH LEAD GENERATION SPECIFIC CAMPAIGNS



Sources: Company Information Notes

1. Due to rounding, the sum of the different numbers could slightly differ from the total

# END-TO-END TRACEABILITY FOR A MORE SUSTAINABLE WORLD



THE POWER OF TRUSTPARENCY TO ENABLE SUPPLY CHAIN VISIBILITY AND CIRCULAR ECONOMY





## SUSTAINABILITY & ENVIRONMENT

### 4R RULE: REDUCE, REUSE, RECYCLE AND RECOVER

ELIMINATION OF THE SALE OF PLASTIC BOTTLES FROM ALL THE DISTRIBUTORS AND INSTALLED DRINKING FOUNTAINS

AMBASSADOR OF THE PLASTICFREE CAMPAIGN TO CHALLENGE CLIMATE CHANGE AND THE EFFECTS OF GLOBAL WARMING IN AN EFFORT TO PROTECT THE PLANET

PAPERLESS CAMPAIGN INCLUDING ALL MACHINE MANUALS TO BE DESIGNED FOR DIGITAL CONSULTATION

## CULTURAL HERITAGE

THE

AV

GREEN

SIDE

COOPERATIONS & PARTNERSHIPS WITH SOME OF THE MAIN UNIVERSITIES AND RESEARCH CENTERS

 $\equiv$ 

## SOCIAL SUPPORT



# ANTARES VISION IS CLOSELY CONNECTED TO THE MANAGEMENT OF THE TERRITORY AND THE COMMUNITY IN WHICH IT OPERATES:

✓ Sponsorship of artistic, musical and traditional craftsmanship projects


✓ Solidarity & volunteering activities, addressed both to employees and local/national community

Supporting education & innovation



# INCLUSIVE STRATEGY, LEVERAGING MULTICULTURAL AND DIVERSE TEAM





| ROLE                                     | YEARS AT<br>ANTARES VISION | EQUITY<br>PARTICIPATION | ROLE   | YEARS AT<br>ANTARES VISION | EQUITY<br>PARTICIPATION |
|--|----------------------------|-------------------------|--|----------------------------|-------------------------|
| AV Chairman, Co-CEO<br>and Co-Founder    | 14                         | ✓                       | Industrial Vision System<br>Manager            | 13                         | $\checkmark$            |
| AV Co-CEO<br>Co-Founder                  | 14                         | ✓                       | Pharma Vision Systems<br>Techhnical Manager    | 14                         | $\checkmark$            |
| AV CFO                                   | 6                          | ✓                       | Inspection Machine<br>Division Software Leader | 12                         | ✓                       |
| Managing Director                        | 3                          | ✓                       | Head of Solution<br>Architect                  | 14                         | ×                       |
| Technical Director                       | 3                          | ✓                       | AV North America<br>GM                         | 8                          | ✓                       |
| Smart Digital<br>Innovation Director     | 3                          | ✓                       | FTS NA & Applied Vision<br>GM                  | 3                          | ×                       |
| Service Director                         | 8                          | ✓                       | AV Asia Pacific                                | 3                          | ×                       |
| HR Manager                               | 3                          | ×                       | <b>G</b> M                                     |                            |                         |
| Marketing &<br>Communication<br>Director | 5                          | ×                       | IMAGO Technologies GM                          | 14                         | ✓                       |
| Inspection Machines<br>GM                | 5                          | ✓                       | AV Rus   | 2                          | ✓                       |
| Sales Director                           | 10                         | √                       | AV Do Brasil GM                                | 8                          | ×                       |
| Quality & EHS Manager                    | 9                          | ✓ /                     | Global Business Strategy<br>Advisor            | 2                          | ×                       |
| General Counsel                          | 3                          | ×                       | Convel Co-CEO and Co-<br>Founder               | 2                          | $\checkmark$            |
| IT & Business Process<br>Manager         | 9                          | ~                       | Convel Co-CEO and Co-<br>Founder               | 2                          | ✓                       |
| R&D Software Director                    | 14                         | ~                       | rfXcel Chairman, CEO &<br>Co-Founder           | 1                          | √                       |

#### Sources: Company Information

Notes

1. Number of headcount Pro-Forma, including Applied Vision, JV - Antares Vision India Private Limited, Orobix (minority stake) and rfXcel

88





Section 8

# **FINANCIAL PERFORMANCE**



The following slides compare the consolidated results of Antares Vision S.p.A. ("Antares Vision") along the 2018 - 2020 period:

- The following financial information is derived from Antares Vision Group's consolidated financial statements for the years ended December 31<sup>st</sup>, 2020, 2019 and 2018, prepared in accordance with IFRS accounting principles as adopted by the European Union
- Antares Vision Group's date of transition to IFRS was January 1, 2018, and the consolidated financial figures for the year ended December 31, 2019 include, as comparative data, financial information for the year ended December 31, 2018 restated for the effects of the transition, as of January 1, 2018, to IFRS
- The consolidated financial information of the Antares Vision Group restated in accordance with IFRS for the year ended December 31, 2018 has been prepared solely for the purpose of its inclusion in the offering documents and presentations relating to the listing

With the aim of providing significant measures for Antares Vision financial results, **EBITDA and EBIT are presented according to their adjusted definitions** in order to express normalized data and to increase the level of comparability

- Adjusted EBIT and EBITDA are obtained by not including in the EBIT the effects of the following items, if applicable:
  - impairment of goodwill, if any
  - other expenses or income of a non-recurring nature, i.e. relating to particularly significant events that are not related to the ordinary
    performance of the relevant business
  - PPA amortization
- Adjusted Net Income is obtained by excluding from the Net Income the following items, if applicable:
  - Non-recurring/extraordinary income and/or expenses
  - The theoretical fiscal impact of the non-recurring items

# **KEY FINANCIAL HIGHLIGHTS**



# KEY FINANCIAL HIGHLIGHTS (Mn €)

|   | 2018A                | 2019A              | 2020A       | CAGR 18A-20A                               |
|---|----------------------|--------------------|-------------|--|
| <b>Revenues</b><br>% growth                 | <b>113.8</b><br>n.a. | <b>122.4</b><br>8% |             | +3.1%<br>(020PF<br>(31.9 Mn <sup>(1)</sup> |
| <b>First Margin</b>                         | <b>72.4</b>          | <b>89.8</b>        | <b>95.9</b> | +15.1%                                     |
| % margin                                    | 64%                  | 73%                | 79%         |  |
| Added Value                                 | <b>55.4</b>          | <b>68.1</b>        | <b>75.0</b> | +16.3%                                     |
| % margin                                    | 49%                  | 56%                | 62%         |  |
| <b>EBITDA Adjusted</b>                      | <b>29.3</b>          | <b>31.5</b>        | <b>29.3</b> | (0.1)%                                     |
| % margin                                    | 26%                  | 26%                | 24%         |  |
| <b>EBIT Adjusted</b> <sup>(2)</sup>         | <b>28.6</b>          | <b>29.6</b>        | <b>25.3</b> | (5.9)%                                     |
| % margin                                    | 25%                  | 24%                | 21%         |  |
| <b>Net Income Adjusted<sup>(3)</sup></b>    | <b>20.1</b>          | <b>19.8</b>        | <b>25.8</b> | +13.3%                                     |
| % margin                                    | 18%                  | 16%                | 21%         |  |
| <b>Recurring Capex</b>                      | <b>1.5</b>           | <b>4.1</b>         | <b>5.1</b>  |  |
| % revenues                                  | 1%                   | 3%                 | 4%          |  |
| <b>Net Debt / (Net Cash)</b> <sup>(4)</sup> | <b>(30.4)</b>        | <b>(15.3)</b>      | <b>29.2</b> |  |
| Leverage (x)                                | n.m.                 | n.m.               | 1.0x        |  |

COMMENTS

- Growth path impacted by COVID-19 outbreak in 2020A, offset by FT System acquisition
- Solid and expanding First Margin and Added Value, reflecting increasing incidence of business segments with higher margins
- EBITDA Adj. 2020A showing resilient margin despite the challenging environment
- Asset-light business model with low Recurring Capex, on average at 3% of Revenues
- Net Cash Position in 2018A and 2019A, while 2020A impacted by significant investments in M&A activity through the acquisitions of Tradeticity, Convel and Applied Vision Corp.

Sources: Company Information

Notes:


- 1. Pro-Forma results including 12m contribution from Tradeticity, Convel, Applied Vision, rfXcel, Pen-Tec and Tecnel
- 2. EBIT Adj. excluding the effect of PPA-GW amortization and bank fees
- 3. Including full Patent Box effect for years 2016A 2019A in 2020A

 Excluding the financial debt related to the issuance of the Warrants in conjunction with AIM Admission for €4.5 Mn in FY 2019A, €4.2 Mn in FY 2020A

# **REVENUES PERFORMANCE BY SEGMENT**



## SMART DATA, SERVICES AND OTHER<sup>(1)</sup>



### COMMENTS

Increasing incidence on Revenues of Services

 (after-sale) and Smart Data Management,
 segments with higher margins

 Inspection significant growth mainly driven by FT


 System and Convel acquisitions, with FT System
 paving the way for the expansion in new end 

markets (e.g. F&B)

• 2020A Track & Trace Revenues negatively impacted in Life Science end-market due to regulation slow-down and delays in projects implementation due to COVID-19 outbreak

# TOP LINE GROWTH COUPLED WITH AN INCREASING DIVERSIFICATION **ACROSS GEOGRAPHIES AND END-MARKETS**





**REVENUES BY END-MARKET** 

Focus on international expansion (with Italy's weight decreasing from 22% in 2018 to 17% in 2020), consolidation of presence in North America further accelerated thanks to recently announced acquisitions


#### Increasing exposure to Food & Beverage mainly thanks to FT System acquisition

#### Sources: Company Information

Notes: 1. Due to roundings, the sum of the different numbers could slightly differ from the total 2. Including Italy

# STRONG FIRST MARGIN AND ADDED VALUE EXPANSION





#### COMMENTS


In 2020A First Margin was up by +6.8%. The positive impact came from lower installation expenses and lower COGS, thanks to the lower recourse to external providers as a consequence from a wider geographic footprint and internal resources, coupled with increasing portion of sales from Smart Data and Services which benefit from higher margins

In 2020A Added Value increased by 10.2% mainly
thanks to a decrease of Services costs


# FOCUS ON PROFITABILITY WHILE INVESTING SIGNIFICANTLY FOR THE FUTURE



## EBITDA ADJUSTED & EBITDA ADJ. MARGIN



## EBIT ADJUSTED & EBIT ADJ. MARGIN<sup>(1)</sup>



## NET INCOME ADJUSTED & NET INCOME ADJ. MARGIN




## COMMENTS

- EBITDA Adj. showed an improvement of +7.4% in 2019A vs. 2018A and a decrease of -7.1% in 2020A vs. 2019A
  - In 2020A EBITDA Adj. showing resilient margin as a result of (i) increase in personnel costs (related to M&A and the implemented hiring policy), (ii) partially offset by the increase in profitability driven by the shift of product mix toward Service and Smart Data Management
- EBIT Adj. 2019A increased by +3.4% vs. 2018A, while 2020A showed a decrease of -14.3% vs. 2019A (as a result of higher amortization linked to the capitalization of development costs and to leased assets accounting)
- On December 10<sup>th</sup> 2020 AV announced the signing of an agreement for the use of the "Patent Box" tax benefit for the period 2016A-2020A. The agreement has been extended also for the period 2021E-2025E
- Through the Patent Box regime, Antares Vision's average consolidated tax rate for the 2016A-2019A period stood at approximately 18% in Italy, compared to 26% prior to the agreement

# CAPEX & R&D EXPENSES OVERVIEW




## CAPITAL EXPENDITURE & CASH CONVERSION <sup>(1)</sup>



## COMMENTS

- Asset light business model with average recurring Capex equal to 3% of total Revenues for the period 2018A – 2020A, allowing for a strong cash conversion (avg. of 88% 2018A – 2020A)
- Recurring Capex include capitalized Development Costs and Tangible & Intangible recurring investments
- Non-recurring Capex include Investments in Tangible and Intangible Non-Recurring Assets, Improvements on Real Estate and IFRS 16 Investments

### **RESEARCH AND DEVELOPMENT EXPENSES**



### COMMENTS

- Constant R&D activity to support new researches
   and projects through the activities of AV Innovation
   Center
- Total Research & Development expenses
   accounting for 8% of Revenues in 2020A


Sources: Company Information Notes:

1. Excluding M&A capex


2. Cash Conversion calculated as (EBITDA Adj. - Recurring Capex) / EBITDA Adj.



## NET WORKING CAPITAL EVOLUTION



## TRADE WORKING CAPITAL EVOLUTION



### COMMENTS

- In 2020A NWC rose significantly largely due to the reduction in contractual liabilities generated by the application of IFRS 15 and partially due to the working capital of the acquired companies and a ramp-up of the Inventory
- Days increase in DSOs between 2018A and 2019A mainly attributable to higher sales to the USA, Russia and South Korea, which led to an increase in receivables at the end of the year
- Days decrease in DPOs between 2018A and 2019A mainly attributable to a review of the payment terms in place with suppliers


## **KEY METRICS**



# CASH GENERATION SUPPORTING EXTERNAL GROWTH



## **OPERATING CASH FLOW GENERATION BREAKDOWN**




### COMMENTS

- Antares Vision was able to generate positive operating cash flow in fiscal years 2020A, 2019A and 2018A as a result of its operating performance
- The cash absorption in investing activities was mainly attributable to:
  - in 2020A, to the acquisitions of Adents,
     Tradeticity, Convel and Applied Vision Corp.
  - in 2019A to the effect of the acquisitions of FT System and T2 Software

# **CAPITAL STRUCTURE**





## COMMENTS

- In 2020A the Net Debt mainly reflects the investments for the acquisitions of Tradeticity, Convel, Adents and Applied Vision Corp., as well as investments in fixed assets and R&D
- Net Cash change between 2018A and 2019A
   mainly due to the effect of:
  - outflows from investments in R&D
  - cash employed for the acquisitions of FT
     System, Orobix, T2 Software
  - preparatory activities for the opening of subsidiaries in Russia, India and Hong-Kong
  - merger with ALP.I with the consequent listing

Sources: Company Information Notes: 1. Net debt/(Net Cash) adjusted for market-to-market warrants





Section 9

# **GROWTH STRATEGY**






# CONSOLIDATED LEADERSHIP ON T&T IN LIFE SCIENCE

1. Based on delivered Track & Trace lines




# FAVOURABLE REGULATORY FRAMEWORK COUPLED WITH AN INCREASING RECOGNITION OF ANTARES VISION AS A REFERENCE IN THE MARKET



# PRODUCT TYPE DIVERSIFICATION IN THE LIFE SCIENCE MARKET




INCREASED PRODUCT TYPE DIVERSIFICATION IN LIFE SCIENCE THANKS TO A ONE-STOP-SHOP MODEL, LEVERAGING EXISTING BROAD CUSTOMER PORTFOLIO AND SALES ORGANIZATION



**REVENUES BREAKDOWN WITHIN LS END-MARKET** 


## **KEY STRATEGIC ACTIONS BY SEGMENT**



# DEVELOPMENT OF CROSS-SELLING IN THE LIFE SCIENCE MARKET



# AV PAVED THE WAY FOR CROSS-SELLING PENETRATION, BY EXTENDING ITS PRODUCT PORTFOLIO TO THE BROAD AND GROWING T&T CUSTOMER BASE



# GROWTH FURTHER ACCELERATED BY A FOCUSED M&A STRATEGY




PROVEN AND DISCIPLINED M&A TRACK-RECORD COUPLED WITH A CONSTANT SCREENING OF M&A OPPORTUNITIES AIMING AT FURTHER GROWTH ACCELERATION, GEOGRAPHIC EXPANSION, CREATING SYNERGISTIC VALUE AND CROSS-SELLING OPPORTUNITIES BY ALSO ENHANCING KNOW-HOW AND PRODUCT EXTENSION

| YEAR   | COMPANY                                 | CORE ACTIVITY                                    | INDUSTRY      | COUNTRY      | ADVANTAGES                     |
|--|---|--|---------------|--------------|--------------------------------|
| SEP 19   | <b>Software</b>                         | DATA MANAGEMENT & SOFTWARE                       |               | ۲            |                                |
| SEP 19   | INSPECTION FOR GUALITY                  | F&B CONTROL & INSPECTION                         |               | $\mathbf{O}$ | GROWTH<br>ACCELERATION         |
| SEP 19   |   | TECHNOLOGICAL PARTNERSHIP                        | =0 <b>1</b>   | $\bullet$    |                                |
| <b>DEC 19</b>  | ାର୍ଡ୍ କ୍ର<br>OROBIX                     | ARTIFICIAL INTELLIGENCE <sup>(1)</sup>           |               |              | SYNERGISTIC VALUE<br>CREATION  |
| APR 20   | <b>TRADETICITY</b>                      | TRACK & TRACE SOFTWARE                           |               | 3            |                                |
| <b>JUN 20</b>  | - COUNDI                                | LIFE SCIENCE CONTROL & INSPECTION                |               |              | GEOGRAPHICAL                   |
| <b>JUN 20</b>  | ima <mark>5</mark>                      | INSPECTION & TRACKING PARTNERSHIP                | € <b>14</b> ↔ |              | EXPANSION                      |
| NOV 20   | in Adents                               | TRACK & TRACE SOFTWARE                           |               |              | CROSS-SELLING<br>OPPORTUNITIES |
| DEC 20   | MPPLIED VISION<br>Simply Smart Machines | MACHINE VISION SYSTEMS                           | € <b>0</b> €  |              | CREATION                       |
| FEB 21   | rfxcel                                  | TRACK & TRACE SOFTWARE                           |               |              | KNOW-HOW AND                   |
| MAR 21   | CLAVIS PEN-TEC TECNEL                   | F&B CONTROL & INSPECTION                         |               |              | PRODUCT EXTENSION              |
|  | A c                                     | $\sim$ $\sim$                                    |               |              |                                |
| <b>Sources:</b> Comp<br><b>Notes</b><br>1. Minority stak |   | d & Beverage 💮 Life Science 🚑 Software Pure-Play | Acquisition   | Partnersh    | ip<br>© 2021 Antares Vision    |

# M&A AS THE LEVER FOR DIVERSIFICATION TO FOOD & BEVERAGE...



# STARTED A PATH OF END-MARKET DIVERSIFICATION BOOSTED BY THE ACQUISITION OF FT SYSTEMS IN 2019 AND RECENTLY APPLIED VISION



#### Sources: Company Information

# ...AND FOR ACCELERATING THE END-TO-END DIGITALIZATION OF THE SUPPLY CHAIN THROUGH THE ACQUISITION OF RFXCEL



## FULL ALIGNMENT WITH ANTARES VISION STRATEGY



Strengthen Software offering across key end-markets



Enhance suite of SaaS capabilities



Drive **customer experience** for digital solutions



Grow share of recurring and contracted digital revenues



Expand Smart Data Services offering



Enable supply chain digitalisation: transparency, inclusivity and sustainability

STRONG FINANCIAL PROFILE

- >25% HISTORICAL REVENUES CAGR<sup>(1)</sup>
  - >85% GROSS MARGIN<sup>(2)</sup>
- >80% RECURRING REVENUES<sup>(2)</sup>
  - SaaS FOCUS ON SOFTWARE AS A SERVICE

## COMPLEMENTARY MARKET EXPOSURE



Sources: Company Information Notes 1. Based on rfXcel reporting fiscal year ending March 2018-20 2. Based on rfXcel LTM Dec-20 Revenues

# **IMPLEMENTED GROWTH FACTORS & ENABLERS**





108






# UNTAPPED ORGANIC GROWTH OPPORTUNITIES SUPPORTED BY PARTNERSHIPS AND EXTERNAL GROWTH OPPORTUNITIES



ANTARES VISION PURSUES A STRATEGY AIMED AT EXPANDING ITS POSITION AS A LEADING WORLDWIDE PROVIDER OF TRACK & TRACE, INSPECTION, SMART DATA MANAGEMENT AND SOFTWARE SOLUTIONS




110

# **4** T&T LEADERSHIP CONSOLIDATION



THE CONSOLIDATION OF THE LEADERSHIP IN T&T WILL BE MAINLY DRIVEN BY INTRODUCTION/EVOLUTION OF THE REGULATORY FRAMEWORK RELATED TO TRACEABILITY

### PRESCRIPTION DRUGS' REGULATION STATUS



1. Further implementation of Serialization in Ukraine and UAE, Aggregation in Bahrain, full regulation in Ethiopia


2. Further implementation of full regulation in Malaysia and Qatar (on primary packaging)

# **ORGANIC GROWTH IN THE LIFE SCIENCE MARKET FURTHER** STRENGTHENED BY SIGNIFICANT CROSS-SELLING OPPORTUNITIES



CROSS-SELLING REPRESENTS A KEY PILLAR FOR THE ORGANIC GROWTH STRATEGY IN LIFE SCIENCE

### STRATEGIC GUIDELINE



Sources: Company Information Notes

1. Ratio between cumulative lines by BU/Service and AV T&T cumulative installed base 2. Visual Cameras On-top installations (not included in T&T lines)

3. Smart data penetration extra service agreement

PENETRATION OF OTHER SEGMENTS' PRODUCTS ON LIFE SCIENCE

TRACK & TRACE INSTALLED LINES (CUMULATIVE<sup>(1)</sup>, 2020A)

# **A3** DRIVERS FOR GROWTH BEYOND LIFE SCIENCE END-MARKETS



CURRENT POSITIONING, COUPLED WITH BRAND AWARENESS AND TECHNOLOGY EXPERTISE, WILL FACILITATE THE EXPANSION IN UNDERPENETRATED MARKETS WHILE MAINTAINING STRONG PROFITABILITY


### **KEY STRATEGIC GUIDELINES**





# **B** SPRINGBOARD PROJECTS





# **©** MERGERS & ACQUISITIONS STRATEGY AND RATIONALE



CONSTANT RESEARCH FOR POTENTIAL COMPANIES TO ACQUIRE, IN ORDER TO CONSOLIDATE LEADERSHIP POSITION IN REFERENCE MARKETS FOSTERING TECHNOLOGICAL ADVANCEMENT

|            | TECHNOLOGY      | <ul> <li>STRENGTHEN TECHNOLOGICAL CAPABILITIES NOT YET AVAILABLE IN AV<br/>CURRENT OFFERING</li> <li>STRENGTHEN COMPETITIVE PRESENCE IN SMART DATA MANAGEMENT AND<br/>DIGITAL SOLUTIONS</li> </ul>          |
|------------|-----------------|---|
| KEY M&A    | DIVERSITY       | <ul> <li>BROADEN GEOGRAPHICAL DIVERSIFICATION EXPANDING IN NEW MARKETS</li> <li>EXPANDING PRODUCTS OFFERING</li> <li>DIVERSIFY AND EXPAND THE CUSTOMER BASE</li> </ul>                                      |
| OBJECTIVES | TALENTS         | <ul> <li>ACQUIRE AND RETAIN HIGHLY QUALIFIED AND EXPERIENCED TALENT</li> <li>STRENGTHEN THE MANAGEMENT TEAM WITH INDUSTRY-EXPERIENCED LEADERS<br/>WITH IN-DEPTH KNOWLEDGE OF LOCAL MARKETS</li> </ul>       |
|            | VALUE ACCRETION | <ul> <li>DISCIPLINED APPROACH</li> <li>SCOUTING OPPORTUNITIES SHOWING BOTH STRONG BUSINESS AND FINANCIAL<br/>RATIONALE WITH STRONG VALUE CREATION POTENTIAL AND ACCRETIVE FOR<br/>ANTARES VISION</li> </ul> |

# **D** ADDITIONAL FACTORS AND ENABLERS



ADDITIONAL SUPPORT TO GROWTH STRATEGY COMING FROM CONTINUOUS TECHNOLOGICAL INNOVATION, ORGANIZATIONAL ENHANCEMENT AND BRAND EQUITY DEVELOPMENT, COUPLED WITH A FOCUS ON ESG AND SUSTAINABILITY








Appendix A

# **SUPPORTING MATERIALS**

### ANTARES VISION GROUP OWNERSHIP STRUCTURE






#### Sources: Company Information Notes:

1. Fabio Cardella 6.0%, Carsten Strampe 5.9%, Armando Bruno Isoli 4.0%, Golden Rule Investments 3.1%, Adriano Fusco 1.5%, Fabio Forestelli 1.0%, Ferdinando Tuberti 1.0%, Alioscia Berto 0.9%, Andrea Gallo 0.5%, Giovanni Lovato 0.5%, Treasury shares: 3.8%

118


# ANTARES VISION GROUP CORPORATE STRUCTURE





# **BOARD OF DIRECTORS (AT IPO)**





120

# **INCOME STATEMENT SUMMARY**



| Figures in € Mn               | 2018A  | 2019A  | 2020A  |
|-------------------------------|--------|--------|--------|
| Revenues                      | 113.8  | 122.4  | 121.0  |
| Capitalization of R&D         | 1.2    | 3.6    | 4.7    |
| Other Tax Credit              | 0.1    | 1.7    | 1.4    |
| Tax Credit                    | 1.0    | 1.0    | 1.2    |
| Value of Production (VoP)     | 116.1  | 128.8  | 128.3  |
| COGS                          | (36.4) | (30.7) | (27.5) |
| Commercial costs              | (3.2)  | (3.1)  | (3.2)  |
| Installation expenses         | (4.0)  | (5.2)  | (1.7)  |
| First Margin                  | 72.4   | 89.8   | 95.9   |
| First Margin % on Revenues    | 63.7%  | 73.3%  | 79.2%  |
| Third party assets            | (1.5)  | (1.4)  | (1.3)  |
| Operating expenses            | (0.1)  | (0.1)  | (0.1)  |
| Services                      | (15.4) | (20.2) | (19.4) |
| Added Value                   | 55.4   | 68.1   | 75.0   |
| Added Value % on Revenues     | 48.7%  | 55.6%  | 62.0%  |
| Labour cost                   | (26.1) | (36.5) | (45.7) |
| EBITDA Adj.                   | 29.3   | 31.5   | 29.3   |
| EBITDA % on Revenues          | 25.8%  | 25.8%  | 24.2%  |
| D&A and provisions            | (0.8)  | (2.0)  | (4.0)  |
| EBIT Adj.                     | 28.6   | 29.6   | 25.3   |
| EBIT % on Revenues            | 25.1%  | 24.1%  | 20.9%  |
| Financial items               | (0.9)  | 2.9    | (4.0)  |
| PPA Amortization              | -      | (0.4)  | (1.5)  |
| Extraordinary and other items | (0.4)  | (3.1)  | (5.1)  |
| Earnings before tax (EBT)     | 27.2   | 29.0   | 14.7   |
| EBT % on Revenues             | 23.9%  | 23.7%  | 12.1%  |
| Taxes                         | (7.5)  | (6.7)  | 3.4    |
| Net Profit                    | 19.8   | 22.3   | 18.1   |
| Minority interest             | 0.0    | (0.4)  | 0.0    |
| Net profit of the group       | 19.7   | 21.9   | 18.2   |
| Net profit % on Revenues      | 17.3%  | 17.9%  | 15.0%  |
|                               |        |        |        |

# BALANCE SHEET SUMMARY



| Figures in € Mn               | 2018A  | 2019A   | 2020A   |
|-------------------------------|--------|---------|---------|
| Tangible assets               | 6.6    | 14.0    | 21.5    |
| ntangible assets              | 2.3    | 66.8    | 106.3   |
| Financial assets              | -      | 3.8     | 4.0     |
| Fixed assets                  | 8.8    | 84.6    | 131.8   |
| nventory                      | 22.2   | 25.6    | 32.3    |
| Frade receivables             | 41.5   | 56.5    | 47.5    |
| rade payables                 | (26.3) | (29.7)  | (29.1)  |
| ſWC                           | 37.4   | 52.3    | 50.7    |
| Other assets                  | 13.5   | 17.2    | 23.2    |
| Other liabilities             | (34.3) | (39.8)  | (27.1)  |
| NMC                           | 16.6   | 29.8    | 46.8    |
| mployees' leaving indemnity   | (2.6)  | (5.7)   | (6.9)   |
| Bad debt and other provisions | (0.5)  | (1.8)   | (3.2)   |
| Net Invested Capital (NIC)    | 22.3   | 106.8   | 168.5   |
| Cash and cash equivalents     | 62.6   | 118.4   | 129.2   |
| inancial debt                 | (27.6) | (99.8)  | (153.9) |
| easing debt                   | (4.6)  | (7.8)   | (8.7)   |
| Gross debt                    | (32.2) | (107.6) | (162.6) |
| let Cash / (Debt)             | 30.4   | 10.8    | (33.4)  |
| Varrant marked-to-market      |        | 4.5     | 4.2     |
| let Cash / (Debt) Adjusted    | 30.4   | 15.3    | (29.2)  |
| Equity                        | 52.7   | 117.6   | 135.2   |
|                               |        |         |         |

# THANK YOU



### LEGAL DISCLAIMER



This document has been prepared by Antares Vision S.p.A. (the "**Company**") for informational purposes in relation to the Company. This document, the information contained herein and any information provided at any oral presentation in connection herewith, including any question and answer session that follows (the "**Materials**"), is in summary draft form for discussion purposes only and must not be relied upon for any purpose.

By accessing this document and/or attending the presentation to which this document relates, you acknowledge that you will be solely responsible for your own assessment of the market and the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business; further, you will be taken to have represented, warranted and undertaken that you understand the legal and regulatory sanctions attached to the misuse, disclosure or improper circulation of the Materials, and have read and agreed to be bound by, and comply with, the contents of this notice.

The Materials have been prepared and issued by, and are the sole responsibility of, the Company and no representation or warranty, express or implied, is given by or on behalf of the Company or any of its affiliates, shareholders, directors, officers, advisers, agents or employees or any other person as to the truthfulness, accuracy, fairness, or completeness of, or for any errors, omissions or misstatements in, the information or opinions given at the presentation or contained in the Materials and/or related materials and no liability is accepted for any such information or opinions or any loss howsoever arising. Any information regarding industry, market and competitive position that comes from third party sources has not been independently verified. Undue reliance should not be placed on any of the industry or market data in the Materials.

The Materials are not intended for potential investors and do not constitute or form part of any offer, or a solicitation of any offer, or a recommendation or inducement to buy or sell securities, and should not be construed as a prospectus or offering document. The Materials are not intended to form the basis of any investment activity, advice or decision and investors should not subscribe for or purchase any shares in the Company on the basis of or in reliance on the information in the Materials. The Company has not decided finally whether to proceed with a transaction.

Information contained in this presentation is a summary only and this presentation does not purport to identify or suggest all of the risks (direct or indirect) that may be associated with an investor's investment in the shares of the Company.

Any purchase of securities in a global offer of the securities of the Company should be made solely on the basis of the information contained in the final prospectus (the "Prospectus") or offering circular (if any) to be issued by the Company in connection with such global offer.

The Materials may include forward-looking statements, which are based on current expectations and projections about future events. These forward-looking statements, as well as those included in any other Material forming part of the preliminary discussions, are solely forecasts reflecting current views with respect to future events and plans, estimates, projections and expectations which are subject to known and unknown risks, uncertainties and assumptions about the Company and its subsidiaries and investments that are in some cases beyond the Company's control, including, amongst other things, the development of its business, trends in its operating industry and future capital expenditure. These risks, uncertainties and assumptions may cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements (and by past results, performance or achievements). Forward-looking statements are not guarantees of future performance and speak only as at the date of this document. Any reference to past performance is not to be taken as an indication of future performance. No one undertakes to update or revise any such forward-looking statement targets, estimates, prospect or returns, if any. You are therefore cautioned not to place undue reliance on any forward-looking statements.

The Company does not intend to register any securities hat it may offer under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and any such securities may not be offered or sold in the United States unless registered under the Securities Act or offered in a transaction exempt from, or not subject to, the registration requirements of the Securities Act. There will be no public offering of the securities in the United States. Neither this document nor any copy of it may be taken or transmitted into or distributed, directly or indirectly, in the United States (other than to qualified institutional buyers, as defined in Rule 144A under the Securities Act) or in Australia, Canada or Japan or to any resident of Australia, Canada or Japan or any other jurisdiction that prohibits the same or to any securities analyst or other person in any of those jurisdictions. Persons into whose possession this document comes should inform themselves about, and observe, any prohibitions or restrictions by law concerning the distribution of this document in other jurisdictions. Any failure to comply with this restriction may constitute a violation of United States or other national securities laws.

These Materials have been prepared on the basis that any public offering will be conducted in Italy pursuant to the Prospectus that will be published following the approval by CONSOB in accordance with applicable laws and regulations. The Materials are not intended for the general public in Italy. Neither this document nor any copy of it may be taken or transmitted into or distributed, directly, or individuals or entities falling outside the definition of Qualified Investors as per Article 34-ter, para. 1, lett. b) of CONSOB Regulation No. 11971/1999 (as amended).

In the United Kingdom, the Materials are intended for, and are directed only at, persons who: (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"); (ii) are persons falling within Article 19(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Order; or (iii) are persons to whom it may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons."). The Materials are intended for Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which these Materials relate are available in the United Kingdom only to Relevant Persons and will be engaged in only with Relevant Persons. These Materials have been prepared on the basis that any offer of shares or other securities in the United Kingdom will be made pursuant to an exemption under Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the "UK Prospectus Regulation") from the requirement to publish a prospectus for the offers of shares or securities. Accordingly, any person making or intending to make an offer in the United Kingdom of securities which are the subject of these Materials may only do so in circumstances in which no obligation arises for the Company or any of the underwriters to publish a prospectus pursuant to Section 85 of the Financial Services and Markets Act 2000 or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation, in each case, in relation to such offer. The Company has not authorized, nor does it authorize, the making of any offer of securities in circumstances in which an obligation arises for the Company or the underwriters to publish or supplement a prospectus for such offer.

These Materials have been prepared on the basis that any offer of shares or other securities in any Member State of the European Economic Area, other than Italy (each a "Member State"), will be made pursuant to an exemption under Regulation (EU) Regulation 2017/1129 (the "Prospectus Regulation") from the requirement to publish a prospectus for the offers of shares or securities. Accordingly, any person making or intending to make an offer in a Member State of securities which are the subject of these Materials may only do so in circumstances in which no obligation arises for the Company or any of the underwriters to publish a prospectus pursuant to Article 1 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation, in each case, in relation to such offer. The Company has not authorized, nor does it authorize, the making of any offer of securities in circumstances in which an obligation arises for the Company or supplement a prospectus for such offer.

These Materials are an advertisement pursuant to (i) the Prospectus Regulation; (ii) Italian Legislative Decree No. 58 of February 24, 1998 (as amended) and CONSOB Regulation No. 11971/1999 (as amended), implementing the Prospectus Regulation, and (iii) the UK Prospectus Regulation.

The Materials do not purport to be all-inclusive or to contain all the information that a recipient may desire in assessing any transactions contemplated therein. The information and opinions contained in the Materials are provided as at the date of the presentation and may be subject to updating, completion, revision and amendment, and such information may change materially. No person is under any obligation to update or keep current the information contained in this presentation and any opinions expressed relating thereto are subject to change without notice.